BioPharma Dive September 5, 2024
New study results show Lilly’s longer-lasting insulin matched daily shots in controlling blood sugar, adding to positive findings the company disclosed in May.
Eli Lilly on Thursday revealed new data that could help it catch rival Novo Nordisk in a race between the two large drugmakers to develop a once-weekly insulin shot.
The Indianapolis-based drugmaker said that, in a pair of Phase 3 trials, its experimental shot controlled blood sugar as well as two commonly used daily insulins in diabetics who either switched from a shorter-acting shot or had never used a longer-lasting one.
One study, dubbed QWINT-1, compared Lilly’s weekly shot, efsitora alfa, to daily injections of insulin glargine, the active ingredient in Sanofi’s Lantus, over the course of...
Today's Sponsors
Today's Sponsor